2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 243-245
Access, Representation, Population Health, Treatment Considerations, Non-Biological Therapies, Opioids, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

578 Successful linkage to care MODEL USED in recruitment and engagement in care to impact practice enhancement (RECIPE) study

Julie Kanter, MD, Wendi Rotunda, PhD2, Marsha Treadwell, PhD3, Lewis L. Hsu, MD, PhD4, Robert Gibson, PhD5, Lisa Cox, PhD6, Andrea Lamont Nazarenko, MA, MAS, PhD7, Nicky Harris8, Shannon Phillips, PhD, RN9, Catherine Viator, MS10, Sara R. Jacobs, PhD11
1 University of Alabama Birmingham, Birmingham, Alabama, United States
2 RTI International, Research Triangle Park, North Carolina, United States
3 University of California at San Fransisco, Oakland, California, United States
4 University of Illinois at Chicago, Chicago, Illinois, United States
5 Medical College of Georgia, Augusta, Georgia, United States
6 RTI International, Research Triangle Park, North Carolina, United States
7 Lamont Consulting, LLC, Lexington, South Carolina, United States
8 University of Alabama Birmingham, Birmingham, Alabama, United States
9 Medical University of South Carolina, Charleston, South Carolina, United States
10 RTI International, Research Triangle Park, North Carolina, United States
11 RTI International, Research Triangle Park, North Carolina, United States

Introduction: Sickle cell disease (SCD) is a genetic disorder associated with progressive multi-organ complications, recurrent pain, and premature mortality. Optimal management requires comprehensive, evidence-based care delivered by SCD specialists to ensure use of disease-modifying therapies and preventive screening. Unfortunately, data from current studies indicate that many adults with SCD are not receiving care from a SCD specialist. Barriers to specialized care are particularly pronounced for individuals in rural areas or those facing socioeconomic disadvantages. Improving access to specialized SCD care is a major priority within the SCD community. 

A key challenge to improving access to SCD care is identifying and engaging individuals not currently in care. Individuals who have not seen a SCD specialist in a non-acute setting for >1 year are considered "unaffiliated." These individuals are often difficult to locate as administrative data only captures people who are seen regularly for care. The Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) study is a National Heart, Lung and Blood Institute sponsored project designed to identify and link unaffiliated individuals with SCD to care. RECIPE adapts an evidence-based linkage-to-care model originally developed for human immunodeficiency virus management, in which linkage coordinators (LCs) help connect people to care. This study leverages implementation science to both find people who are unaffiliated from care and optimize care LC engagement.

Methods: RECIPE was initiated at 4 established SCD centers (Wave 1) and initial findings will then be applied to a second wave of sites.  We analyzed data from the four Wave 1 sites: University of Alabama-Birmingham, University of California at San Francisco, University of Illinois at Chicago and Augusta University with the objective to understand which implementation pathway was most successful for identifying and recruiting unaffiliated patients with SCD to care. Referral sources were grouped into predefined implementation pathways: 1) hospital-based pathway (e.g., referrals from emergency departments, inpatient hospital stays, OBGYN); 2) community-based pathway (e.g., referrals from community-based organizations); 3) surveillance-informed care re-engagement pathway (e.g., identifying individuals through existing databases) and 4) self-referral pathway. For each referred individual with SCD, LCs prospectively recorded the referral source, the number of contact attempts, successful contacts, first appointment scheduled and visit attendance. All individuals with SCD referred to a LC between 2022 and 2026 were included.  We conducted descriptive analyses on the referral pathways used and the number of attempts required to contact individuals. We also measured reach (the proportion of individuals successfully contacted by a LC out of all individuals referred to the LC) and care engagement (defined as completion of a non-acute SCD visit).

 Results: From June 2022 - April 2026, 802 individuals with SCD were identified by RECIPE Wave 1 sites, of whom 570 (71.1%) were unaffiliated from SCD care. Most (N=758, 94.5%) had a documented referral source aligned with an implementation pathway. The hospital-pathway was most common (N=429,56.6%) and the surveillance-informed care re-engagement pathway was the second most common (N=207, 27.3%). LCs successfully reached 70.7% (N=567) of referred patients most of whom were contacted </=3 attempts (N=564, 70.3%). Forty-four percent (N=354) of the patients attended at least one visit and 34.8% attended two visits (N=279). There was significant site variation in the number of patients referred and successfully contacted, implementation pathway used, and the number of patients successfully brought into care. Challenges to care engagement also varied significantly by site and will be explored in detail.

 Conclusions: SCD is a chronic condition that requires lifelong expert care. The linkage to care model implemented in RECIPE successfully identified and engaged previously unaffiliated adults with SCD into specialty care. Most individuals were identified using the hospital or surveillance pathways many of whom had never seen a SCD specialist, emphasizing the importance of this work. Overall, LCs successfully reached most referred patients, and almost half of these individuals were subsequently engaged in SCD specialty care.

Julie Kanter, MD: NIH - Research Funding; Sanofi - Research Funding; CDC - Research Funding; HRSA - Research Funding; BMS - Research Funding; Novo Nordisk - Research Funding; Beam Therapeutics - Research Funding; Terumo - Research Funding; Beam Therapeutics - Consultancy (Includes expert testimony); Disc Therapeutics - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Fulcrum - Consultancy (Includes expert testimony); Gamida Cell - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nuvamid - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Abt - Consultancy (Includes expert testimony)